Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 155Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Large B-Cell, Diffuse 26Lymphoma 25Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 22Recurrence 21Neoplasms, Plasma Cell 19Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 8Smoldering Multiple Myeloma 8Hodgkin Disease 8Prostatic Neoplasms 7Lymphoma, B-Cell 6Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Hematologic Diseases 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Leukemia, Myelomonocytic, Chronic 4Immunoblastic Lymphadenopathy 4Anemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Lymphoma, T-Cell, Cutaneous 3

Interventions

Azacitidine 2midostaurin 1Vorinostat 1Nivolumab 1Lenalidomide 1Injections 1Decitabine 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × GATA2 Deficiency × Lenalidomide × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡